MAY 13, 2020 8:18 AM PDT

FDA Fast Tracks Vaccine for COVID-19

WRITTEN BY: Annie Lennon

Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental COVID-19 vaccine for a Phase II trial. 

The vaccine, known as mRNA-1273, was developed by both Moderna and the National Institutes of Health. It was the first candidate to enter a Phase I human trial in March. Although the results of this trial remain unpublished, the FDA granted them federal approval to continue their research via Phase II trial soon. Meanwhile, the company hopes to begin phase III trials, the final trialing phase, early this summer. 

One of the reasons for the vaccine’s swift approval is that it operates via a system used to make other vaccines that has shown to be both effective and without huge risk to patients’ health. Rather than using an inactive form of COVID-19, this method instead introduces patients to synthetic RNA molecules in the hope that their body will recognize them as the virus and produce antibodies that may also fight against the real thing. 

In the vaccine’s Phase II trial, the researchers aim to assess the safety, reactogenicity and immunogenicity of two vaccinations given 28 days apart. They hope to recruit 600 healthy volunteers aged 18 and over, and will then follow each of them for 12 months after the second vaccination. 

Should the vaccine pass the Phase II trial, Moderna anticipates working closely with the US government to decide where its first doses will be delivered. To this end, the company has already begun scaling up its manufacturing capacity to rapidly distribute the vaccine once available. 

Optimistic, the company’s CEO Stephane Bancel nevertheless said that even if approved, supply of the vaccine will remain constrained for some time. Due to the number of cases of the virus globally, he added that soon, there will likely be more than one vaccine in circulation to fight the virus. 

 

Sources: CNBC, LabRoots, Clinical Trials Arena

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 23, 2021
Cancer
Repurposed Antibiotics Show Promise Against Skin Cancer
JUL 23, 2021
Repurposed Antibiotics Show Promise Against Skin Cancer
In experiments with mice, researchers from the Netherlands have found that some antibiotics may be effective in tre ...
JUL 29, 2021
Drug Discovery & Development
A low-cost drug for the treatment of hepatitis.
JUL 29, 2021
A low-cost drug for the treatment of hepatitis.
      The viral disease, Hepatitis C, is known as a silent killer. Hepatitis C is easily spread thro ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
SEP 13, 2021
Cell & Molecular Biology
Could This Drug Delivery Capsule Replace Injections?
SEP 13, 2021
Could This Drug Delivery Capsule Replace Injections?
Antibodies are naturally produced by many organisms, as part of immune defense. They also have potential as a therapeuti ...
SEP 24, 2021
Drug Discovery & Development
Nasal Drugs Show Promise for Slowing Parkinson's Disease
SEP 24, 2021
Nasal Drugs Show Promise for Slowing Parkinson's Disease
Two drugs delivered via the nose have shown promise for improving symptoms of Parkinson's disease in mice. The corre ...
Loading Comments...